Comprehensive Guidelines and Validation Parameters for Near-Infrared Spectroscopic Methods in Pharmaceutical Applications

Dr. Subhadip Banerjee, PhD in Pharmacy
Chief Product Officer. METASPEQ NIR
Contact-info@metaspeq.com

I. Introduction to Near-Infrared (NIR) Spectroscopy in Pharmaceuticals

A. Fundamental Principles and Advantages of NIR Spectroscopy

Near-Infrared (NIR) spectroscopy is a vibrational spectroscopic technique operating in the electromagnetic spectrum typically ranging from 780 nm to 2526 nm (3959 cm^{-1} to 12820 cm^{-1}).[1] Light absorption in this region primarily results from overtones and combinations of fundamental vibrational bands found in the mid-infrared (MIR) region, predominantly involving hydrogen bonds within functional groups such as –CH, hydroxyl (–OH), amide (–NH), and thiol (–SH).[1] Unlike ultraviolet (UV) spectroscopy, NIR yields multivariate spectra, providing a rich dataset that contains information on both the physical characteristics (e.g., tablet hardness, coating thickness) and chemical composition (e.g., drug content, polymorphic form) of samples.[1] This multivariate nature allows for comprehensive material characterization from a single measurement.[1]

The advantages of NIR spectroscopy in pharmaceutical applications are substantial. It is recognized as a highly efficient, non-destructive, and non-invasive method, offering fast acquisition times and requiring minimal to no sample preparation.[2] Its ability to utilize probes enables in-situ process measurements, providing instant data access crucial for rapid decision-making during both product development and manufacturing.[4] Furthermore, as a solvent-free technique, NIR aligns well with principles of Green Chemistry, reducing waste and environmental impact.[2] These inherent benefits position NIR as a powerful analytical tool capable of streamlining pharmaceutical processes.

B. Diverse Applications Across Pharmaceutical Manufacturing and Quality Control

NIR spectroscopy's versatility is a cornerstone of its utility in the pharmaceutical industry. It is currently the only technology capable of being deployed across nearly

METASPEQ NIR

every step of the tablet manufacturing process.[1] This includes critical stages such as raw material identification, assessment of blend homogeneity, comprehensive tablet characterization, and precise end-point determination for critical process parameters (CPPs) like blending, granulation, and drying.[1]

Key applications of NIR spectroscopy in pharmaceutical quality control and manufacturing include:

- **Raw Material Characterization:** NIR is widely used by excipient manufacturers for characterizing the physical, chemical, and optical properties of both Active Pharmaceutical Ingredients (APIs) and excipients.[1] Its sensitivity to moisture content is particularly valuable, allowing for differentiation between bound and unbound water, an advantage over conventional techniques like Karl Fisher titration.[1]
- **Blend Homogeneity:** As a non-destructive tool, NIR is crucial for in-line determination of blend uniformity, effectively eliminating issues caused by traditional sample thieves used in content uniformity testing.[1]
- **Granulation and Drying:** NIR is applied for both in-line and off-line moisture determination, particle size distribution analysis, and monitoring the end-points of granulation and drying processes, ensuring optimal granule properties.[1]
- **Tablet Characterization:** The technique facilitates the non-destructive quantification of multiple tablet attributes, including drug content, hardness, dissolution, and coating thickness, from a single measurement.[1]
- **Process Analytical Technology (PAT):** NIR is a fundamental Process Analytical Technology (PAT) sensor for the continuous monitoring of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) in real-time.[4] This enables the development of data-driven control strategies and facilitates real-time product release.[4]

Historically, pharmaceutical quality control relied heavily on off-line, often destructive testing, introducing significant time lags between sampling and obtaining results.[4] The advent of NIR, however, offers non-destructive, real-time, and in-situ measurements across multiple process steps.[1] This capability, particularly as a PAT tool, enables continuous monitoring of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs), facilitating data-driven control strategies and even real-time product release.[4] This represents a fundamental shift from a "test-at-the-end" quality control paradigm to a "quality-by-design" and "quality-in-process" approach. This transition, significantly accelerated by NIR, leads to enhanced operational efficiency, reduced waste through minimized sampling and reagent use, faster product availability, and ultimately, improved patient safety due to more consistent product

METASPEQ NIR

quality. It moves the industry towards a more agile and responsive manufacturing environment, lessening reliance on manual adjustments and mitigating the potential for human error.[4]

II. Regulatory Landscape for NIR Method Validation

A. International Council for Harmonisation (ICH) Q2(R2) Guidelines

1. Evolution and Scope of the Revised Guideline

The International Council for Harmonisation (ICH) Q2(R2) guideline represents a complete revision of its predecessor, Q2(R1), designed to incorporate more recent applications of analytical procedures and to align seamlessly with ICH Q14, the guideline on Analytical Procedure Development.[6] This revision reflects the latest scientific advancements in analytical procedures and introduces a groundbreaking approach to validation, embracing both traditional and modern techniques.[6]

A significant change in Q2(R2) is its expanded scope, which now explicitly includes validation principles for advanced analytical procedures such as mass spectrometry and various spectroscopic techniques, including Near-Infrared (NIR), Raman, and Nuclear Magnetic Resonance (NMR).[7] The guideline also extends its applicability to biologics and other advanced therapies, addressing the evolving landscape of pharmaceutical products.[7] Furthermore, Q2(R2) introduces new concepts relevant to validation throughout a procedure's lifecycle, such as revalidation, co-validation, and platform analytical procedures.[7] A notable addition is Annex 1, which introduces the concept of Multivariate Calibration, acknowledging its growing importance in modern analytical methods.[6] The ICH Q2(R2) and Q14 guidelines reached Step 4 adoption by the Regulatory Members of the ICH Assembly in March 2022 [6], with their availability as final guidances announced by the U.S. Food and Drug Administration (FDA) in March 2024.[8]

2. Interplay with ICH Q14 (Analytical Procedure Development)

The ICH Q2(R2) and Q14 guidelines were developed in parallel and are intended to be complementary, collectively covering the entire spectrum of activities from analytical procedure development through validation and lifecycle management.[6] While Q2(R2) provides guidance for demonstrating that an analytical procedure is fit for its intended purpose, Q14 focuses on the scientific principles and risk-based approaches for developing suitable analytical procedures.[6] ICH Q14 encourages a systematic approach to procedure development, whether through a minimal (traditional) method or by incorporating elements of an enhanced approach, and specifically addresses the development of multivariate analytical procedures and real-time release testing.[7]

METASPEQ NIR

The combined application of these guidelines aims to enhance regulatory communication between the pharmaceutical industry and regulatory bodies, thereby facilitating more efficient and scientifically sound approval processes, as well as post-approval change management of analytical procedures.[6]

3. General Framework for Analytical Procedure Validation

The overarching objective of analytical procedure validation, as articulated in ICH Q2(R2), is to demonstrate that the analytical procedure is unequivocally "fit for the intended purpose".[6] This guideline applies to new or revised analytical procedures used for release and stability testing of commercial drug substances and products, encompassing both chemical and biological/biotechnological entities.[6] It can also be applied to other analytical procedures that form part of the control strategy, following a risk-based approach.[6]

A validation study is meticulously designed to provide sufficient evidence that the analytical procedure meets its objectives, which are defined by a suitable set of performance characteristics and related performance criteria.[9] Prior to conducting the study, a comprehensive validation protocol must be generated. This protocol should detail the intended purpose of the analytical procedure, the specific performance characteristics slated for validation, and their corresponding acceptance criteria.[9] The results of the validation study are then summarized in a validation report.[9] The guideline also specifies that the reportable range of an analytical procedure is typically derived from product specifications and must be confirmed by demonstrating acceptable accuracy, precision, and specificity across this range, inclusive of the upper and lower specification or reporting limits.[6]

The complete revision of ICH Q2(R2), explicitly including advanced techniques like NIR, and its parallel development with Q14, which focuses on analytical procedure development, indicates a concerted global effort by regulatory bodies to modernize analytical procedure oversight. The FDA's adoption of these guidelines further emphasizes this drive towards global harmonization.[8] This represents a fundamental shift from a prescriptive, static validation approach to a more dynamic, science- and risk-based lifecycle management. This harmonization reduces duplicative efforts for pharmaceutical companies operating globally, fosters innovation by providing clear pathways for advanced technologies like NIR, and ultimately streamlines drug development and approval processes while maintaining high quality standards. The explicit inclusion of multivariate calibration in Annex 1 of Q2(R2) is a direct response to the increasing adoption of PAT tools like NIR, validating their scientific rigor and regulatory acceptance.

METASPEQ NIR

B. U.S. Food and Drug Administration (FDA) Guidance for Industry: Development and Submission of Near Infrared Analytical Procedures

1. Applicability and Key Objectives

The U.S. Food and Drug Administration (FDA) has published a specific "Guidance for Industry: Development and Submission of Near Infrared Analytical Procedures," which provides recommendations for the development, validation, and use of NIR-based analytical procedures.[11] This guidance is intended to aid applicants in evaluating the identity, strength, quality, purity, and potency of drug substances and drug products.[11] The recommendations apply to new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplemental NDAs and ANDAs for small molecule drugs, as well as drug substances and drug products covered in Type II drug master files.[11] It is important to note that this FDA guidance focuses solely on the development and validation of NIR analytical procedures and does not provide recommendations concerning the setup, qualification, maintenance, or calibration of NIR instruments.[11] Although specific to NIR spectroscopy, the validation concepts outlined in this guidance can be broadly applied to other multivariate analytical techniques, such as Raman spectroscopy.[12]

2. Detailed Recommendations for NIR Model Development

The FDA guidance outlines a structured approach for the development of NIR models, which are categorized as either quantitative (e.g., for assay) or qualitative (e.g., for identification).[13] The development process typically involves six key steps: construction of a calibration set, presentation of samples, development of chemometric models, internal validation of identification libraries, internal validation of quantitative calibration models, and development of rate-of-change models.[11]

Construction of a Calibration Set: This is a critical initial step. The calibration set must include samples that span an appropriate concentration range for the component being analyzed and must account for all potential sources of variability. These sources include variations in processes, the analyzer itself, physical characteristics of materials, water content, temperature, and even materials from multiple vendors or different manufacturing lots.[13] Ideally, calibration samples should closely mimic those expected from the commercial process, preferably originating from batches produced at the intended commercial scale or representative of it, as these naturally exhibit expected process variability.[13] If process samples do not provide sufficient variability, additional samples can be prepared under laboratory conditions, ensuring their physical attributes yield a spectral response similar to

METASPEQ NIR

commercially manufactured materials.[13] For quantitative NIR models, analyte concentrations should span a range wider than the acceptable specification limit to enable characterization of nonconforming materials. When characterizing multiple analytes simultaneously, the use of Design of Experiment (DoE) methodology is recommended for selecting the optimum combination of analyte concentrations.[13]

Presentation of Samples: The method of sample presentation can significantly influence spectral quality and, consequently, the performance of the NIR analytical procedure.[13] Applicants should select an option (e.g., diffuse reflectance/transmission measurements, single/multiple sample holders, different probe window sizes, individual fibers) that best suits the procedure's requirements. Consistency between the interface and sample presentation used for calibration and routine production sample spectra is paramount.[13]

Development of Chemometric Models: NIR chemometric models are typically built upon wavelength-dependent spectral intensities or their linear combinations. Common algorithms include Principal Component Analysis (PCA), Partial Least Squares (PLS), and Principal Component Regression (PCR).[13] The selection of the wavelength range does not necessarily need to encompass the full analyzer range, but restricting it to narrow regions around an analyte peak can compromise robustness.[13] Raw NIR spectra usually require pretreatment to reduce variability and enhance spectral effects related to chemical composition (e.g., minimizing the impact of particle size or compression force).[13] The appropriate number of factors or latent variables must be chosen carefully to avoid underfitting or overfitting, with most software providing statistical tools for this determination.[13] Potential outliers (e.g., samples with high leverages or residuals, atypical spectra or reference results) must be investigated, and their inclusion or exclusion justified.[13] For active ingredient content in tablets, calibration models should be developed using reference assay values from individual tablets based on matched weight and concentration, with routine analysis requiring correction of the NIR concentration result for each tablet's weight.[13]

Internal Validation: Internal validation, sometimes referred to as internal testing, is performed during the model development phase to optimize the model and estimate its performance.[9] Two common approaches are cross-validation using the calibration set or validation using an independent internal validation set.[13] In cross-validation, one or more spectra are successively removed from the calibration set, a model is built on the remaining spectra, and applied to the removed spectra, with residuals used to calculate the root mean square error of cross-validation (RMSECV).[2] For an internal validation set, one or more models from the calibration set are applied to this

METASPEQ NIR

independent set, and residuals are used to calculate the standard error of prediction (SEP).[13] It is critical to understand that internal validation is *not* a substitute for external validation.[11]

Development of Rate-of-Change Models: These models are typically employed to monitor and detect the endpoint of dynamic processes, such as blending or mixing, where the endpoint coincides with the measured rate of change reaching a predefined threshold.[13] Models can be based on changes in concentration of active ingredients or other components, or spectral magnitude.[13] Endpoint criteria should ensure the detected endpoint is not transient and, for blends with low-concentration components, indicate uniform distribution of the low-level component, not just major components.[13]

3. Requirements for External Validation of NIR Analytical Procedures

External validation is a mandatory step that must be performed *after* the chemometric models have been developed.[11] This validation requires a set of samples that are independent from those used in calibration and internal validation.[13] These samples must span a suitable range of operating conditions, including those expected in commercial production, and be sufficiently numerous to yield statistically meaningful results.[13] Ideally, they should be produced at the intended commercial scale or be representative of the commercial process.[13] Results for external validation samples should be acquired from both the NIR procedure and a suitable reference analytical procedure (e.g., a validated or pharmacopoeial method) using the same sample whenever feasible, or by using representative samples with appropriate justification.[13]

The FDA guidance specifies the validation parameters for different types of NIR analytical procedures:

- **Qualitative Analytical Procedures:** These procedures must be validated for specificity and robustness.[13] Specificity is demonstrated by achieving correct pass/fail results with both positive controls (known identity, confirmed by independent reference testing) and negative controls (placebos or spectrally similar samples).[13]
- **Quantitative Analytical Procedures:** These procedures require validation for accuracy, precision, specificity, linearity, range, detection and quantitation limits, and robustness.[9]
    - **Accuracy:** Demonstrated by comparing NIR procedure results (from external validation samples) with a suitable reference analytical procedure.[9] The Standard Error of Prediction (SEP) can serve as a measure of accuracy. Significant differences between the Standard Error of Calibration (SEC) and

METASPEQ NIR

SEP, or observed biases, necessitate further investigation.[13]
    - **Precision:** Repeatability, measured as the standard deviation of repeat measurements, is a useful indicator.[13] Samples should cover expected variation, with multiple measurements per sample, and the sample should ideally be repositioned in the holder after each measurement.[13] Intermediate precision, involving different analysts or days, should also be determined.[13]
    - **Specificity:** Verified if the main features of the loadings plots correspond to the analyte's NIR spectrum loadings plots (after identical pretreatment).[9] The ability to reject outliers also contributes to specificity.[13]
    - **Linearity:** Assessed by comparing NIR results for external validation samples to reference procedure results.[9] A correlation coefficient near 1 and a y-intercept near 0 (if applicable) indicate acceptable linearity when plotted.[13]
    - **Robustness:** Addressed during calibration model development by incorporating anticipated variability sources (e.g., raw materials, operating/environmental conditions).[9] This is subsequently confirmed during validation using validation samples that encompass commercial production variability.[13]
- **Rate-of-Change Procedures:** Validation of these procedures involves demonstrating the adequacy of the NIR endpoint criteria and their specificity for the components of interest.[13] Endpoint adequacy is confirmed using appropriate reference methodology (e.g., traditional blend uniformity analysis), ensuring the procedure is stopped as soon as criteria are met to avoid misleading results.[13] Specificity is demonstrated by showing that the wavelength region used for the NIR procedure includes major bands of the components of interest.[13]

4. Information Submission Requirements for Regulatory Applications

Applicants are required to provide comprehensive information about every NIR analytical procedure that is part of their commercial control strategy, including detailed development and validation data.[11] High-level summaries of life cycle maintenance plans for these models should also be submitted, while detailed plans and records of software version changes must be maintained at the manufacturing site and readily available for inspection.[13] Information intended solely for developmental or informational purposes does not need to be included in the submission.[13] If both an NIR method and an equivalent traditional method are submitted, their respective roles (e.g., routine release versus alternate method) must be clearly indicated.[13]

Key elements for submission include:

- **Procedural Information:** This encompasses the purpose of the procedure, its

METASPEQ NIR

location within the process, mode of measurement (in-line, on-line, at-line, off-line), the property or attribute measured, and its intended use (e.g., in-process or end-product release).[11] It also requires details on the analyzer and software specifications, sample analysis steps, and, for in-line or on-line methods, information on the instrument interface, cleanliness procedures, spectral acquisition triggers, process endpoint criteria, and contingency plans for analyzer failure.[13]

- **Development Information:** This section requires details on the calibration and internal validation sets, including associated batches, sample numbers, and the distribution of reference values for quantitative procedures.[11] It also necessitates a rationale for the wavelength range, spectral pretreatment, algorithm, and threshold used for chemometric models, along with details on outlier handling and raw/pretreated spectra.[13] For in-line or on-line blending/mixing methods, estimation and justification for the effective sample size and rate-of-change-based method with supporting data for endpoint criteria are required.[13]
- **Validation Information:** This includes details on the external validation set, validation results for quantitative (specificity, linearity, accuracy, precision, robustness) and qualitative methods, the reference analytical procedure and its standard error, and data demonstrating the model's validity at commercial scale.[11] A high-level summary of procedure maintenance, including frequency, methods, and acceptance criteria for periodic model verification and triggers for unscheduled verification, is also necessary.[13]

The FDA's decision to issue a specific guidance document solely for NIR analytical procedures, detailing unique requirements for calibration set construction, internal versus external validation, and chemometric model development, indicates that regulators recognize the inherent complexities and multivariate nature of NIR data, which differ significantly from traditional univariate analytical methods.[11] A generic validation approach is therefore deemed insufficient. This underscores the importance of building robust models that account for real-world variability in pharmaceutical manufacturing. It also highlights a shift towards a lifecycle approach, where model maintenance and revalidation are critical throughout the product's life, not just at initial submission. This ensures continued fitness-for-purpose and regulatory compliance for these advanced PAT tools.

METASPEQ NIR

III. Core Validation Parameters, Methodologies, and Acceptable Criteria for NIR Methods

A. Definitions and Relevance of Key Validation Parameters

The validation of Near-Infrared (NIR) spectroscopic methods in pharmaceutical applications adheres to a set of core parameters, each with a specific definition and relevance to ensuring the method's fitness for its intended purpose. These parameters are crucial for establishing the reliability and robustness of NIR analytical procedures.

- **Accuracy:** This parameter expresses the closeness of agreement between a measured value (or set of values) and a value accepted as either a conventional true value or an accepted reference value.[9] For NIR methods, accuracy is often reported as the Standard Error of Prediction (SEP) or Root Mean Square Error of Prediction (RMSEP).[9]
- **Precision:** Precision quantifies the closeness of agreement (or degree of scatter) among a series of measurements obtained from multiple samplings of the same homogeneous sample under prescribed conditions.[9] Precision can be assessed at three levels: repeatability (intra-assay precision), intermediate precision (inter-assay precision, e.g., different analysts or days), and reproducibility (inter-laboratory precision).[9]
- **Specificity/Selectivity:** These terms describe the extent to which other substances interfere with the determination of an analyte by a given analytical procedure.[9] Specificity denotes the ultimate state of unequivocally measuring a desired analyte, while selectivity is a relative term indicating the ability to measure particular analytes in mixtures or matrices without interference from similar components.[9] For NIR, this involves comparing the drug substance spectrum with the loading plots of the model and demonstrating the ability to reject outliers.[9]
- **Range:** The range of an analytical procedure is defined as the interval between the lowest and the highest results within which the procedure demonstrates a suitable level of precision, accuracy, and response.[9] The *reportable range* specifically includes all values from the lowest to the highest reportable result for which there is a suitable level of precision and accuracy.[9]
- **Response:** This refers to the analytical procedure's capacity (within a given range) to obtain a signal that is effectively related to the concentration (amount) or activity of the analyte in the sample through a known mathematical function.[9]
- **Robustness:** Robustness is a measure of an analytical procedure's capacity to meet its expected performance criteria during normal use.[9] For NIR, this is primarily addressed during calibration model development by incorporating

METASPEQ NIR

anticipated sources of variability into the data set.[9]

Table 1: Summary of ICH Q2(R2) Validation Parameters and Their Application to NIR Spectroscopy

Validation Parameter	Definition (ICH Q2(R2))	Application/Methodology for NIR (Multivariate Calibration)
Accuracy	Closeness of agreement between the measured value and the accepted reference value.	Comparison with an orthogonal procedure across the range (e.g., 5 concentrations, 3 replicates); typically reported as SEP or RMSEP.
Precision	Closeness of agreement (degree of scatter) between a series of measurements from multiple samplings of a homogeneous sample.	**Repeatability:** Repeated analysis with removal of sample from holder between measurements.
Specificity/Selectivity	Extent to which other substances interfere with analyte determination. Specificity is unequivocal measurement; selectivity is relative measurement in mixtures.	Absence of interference: Comparison of drug substance spectrum and the loading plots of the model. Rejection of outliers (e.g., excipient, analogues) not covered by the multivariate procedure.
Range	Interval between lowest and highest results with suitable precision, accuracy, and response.	**Reportable Range:** Includes all values from lowest to highest reportable result with suitable precision and accuracy.
Response	Ability (within a given range) to obtain a signal effectively related to analyte concentration/activity by a known mathematical function.	Demonstration of the relationship between predicted and reference values.
Robustness	Capacity to meet expected performance criteria during	Deliberate variation of parameters (e.g.,

	normal use.	chemical/physical factors impacting NIR spectrum and model prediction) represented in data sets (e.g., various sources of drug substance/excipients, water content, tablet hardness, orientation).

B. Specific Validation Methodologies for Multivariate Calibration Models

The validation of multivariate calibration models, which are central to NIR spectroscopic methods, typically follows a two-phase approach: model development (first phase) and model validation (second phase).[9] In the first phase, calibration data are utilized to create the calibration model, and test data are employed for internal testing and optimization of the model.[9] This internal testing step is crucial for estimating model performance and fine-tuning algorithm parameters, such as the number of latent variables for Partial Least Squares (PLS), to select the most suitable model within a given dataset.[9] This phase assesses the suitability of the coefficient of determination for calibration (R^2cal), the root mean square error of calibration (RMSEC), and the root mean square error of cross-validation (RMSECV).[2] The second phase, model validation, involves using an independent validation set for the external validation of the model.[9] This phase evaluates the coefficient of determination for prediction (R^2pred) and the root mean square error of prediction (RMSEP).[2]

1. Calibration Set Construction and Chemometric Model Development

The foundation of a robust NIR method lies in the meticulous construction of its calibration set. This set must comprise samples that span the appropriate concentration range and comprehensively capture all potential sources of variability relevant to the pharmaceutical process. This includes variations arising from the manufacturing process itself, the analytical instrument, physical characteristics of the materials (e.g., particle size, polymorphism), water content, temperature fluctuations, and even differences between multiple vendors or manufacturing lots of raw materials.[13] Ideally, these calibration samples should closely mimic those encountered in commercial production, or laboratory-prepared samples should be designed to ensure similar spectral responses and physical attributes.[13]

Chemometric models are then developed using algorithms such as Principal Component Analysis (PCA), Partial Least Squares (PLS), and Principal Component Regression (PCR), which operate on wavelength-dependent spectral intensities.[13]

METASPEQ NIR

Critical aspects of model development include the judicious selection of wavelength ranges, the application of appropriate spectral pretreatments (e.g., derivatives, normalization) to reduce unwanted variability and enhance chemical effects, and the determination of the optimal number of factors or latent variables to prevent underfitting or overfitting.[13] Any outliers within the dataset must be thoroughly investigated, and their inclusion or exclusion from the model justified.[13]

2. Internal Validation Approaches (Cross-Validation, Internal Validation Set)

Internal validation, also referred to as internal testing, serves the purpose of optimizing the chemometric model and providing an initial estimate of its performance during the development phase.[2] Two common approaches are employed for this:

- **Cross-Validation:** This technique involves systematically removing a subset of spectra from the calibration set, building a model with the remaining data, and then applying this model to predict the values for the removed spectra.[2] This process is repeated sequentially across the entire calibration set, and the resulting residuals are used to calculate the Root Mean Square Error of Cross-Validation (RMSECV).[2]
- **Internal Validation Set:** Alternatively, an independent subset of samples from the calibration set can be designated as an internal validation set.[13] One or more models derived from the calibration set are then applied to this internal validation set, and the resulting residuals are used to calculate the Standard Error of Prediction (SEP).[13]

It is crucial to emphasize that while internal validation is vital for model optimization, it is explicitly stated by regulatory bodies that it is *not* a substitute for external validation.[11]

3. External Validation Requirements and Sample Considerations

External validation is a critical step performed *after* the chemometric model has been fully developed and optimized.[2] This validation utilizes an independent set of samples that were not involved in either the calibration or internal testing phases.[9] These external validation samples must be representative of the real-world application, spanning a suitable range of operating conditions, including those encountered during commercial production.[13] They must also be sufficiently numerous to ensure statistically meaningful results and should ideally be produced at the intended commercial scale or be fully representative of the commercial process.[13] For accurate comparison, samples should be analyzed by both the NIR procedure and a suitable reference analytical procedure (which should itself be validated or pharmacopoeial).[9] This dual analysis should be performed on the same samples whenever feasible and

METASPEQ NIR

within a reasonable timeframe to ensure sample and measurement stability.[9] The performance of the reference analytical procedure should meet or exceed the expected performance of the multivariate NIR analytical procedure.[9]

C. Discussion of Acceptable Limits and Performance Criteria

The overarching principle guiding acceptable limits and performance criteria for NIR methods is that the analytical procedure must be demonstrated as "fit for the intended purpose".[9] Regulatory requirements often stipulate specific acceptance limits, such as a 5% limit for pharmaceutical specialties in the context of accuracy profiles.[2]

1. Accuracy (e.g., Standard Error of Prediction (SEP), Root Mean Square Error of Prediction (RMSEP))

Accuracy for quantitative NIR procedures is demonstrated by comparing the results obtained from the NIR method on external validation samples with those from a suitable reference analytical procedure.[9] This comparison should be conducted across the entire analytical range, utilizing an appropriate number of determinations and concentration levels (e.g., 5 concentrations with 3 replicates each).[9] Accuracy is typically reported as the Standard Error of Prediction (SEP) or Root Mean Square Error of Prediction (RMSEP).[9] Any significant differences observed between the Standard Error of Calibration (SEC) and SEP, or the presence of systematic biases, necessitate thorough investigation.[13]

A more advanced and robust approach to evaluating accuracy and linearity is the use of **accuracy profiles**, which are based on β-expectation tolerance intervals.[2] An accuracy profile defines an interval where a specified proportion (β) of NIR results are expected to fall.[2] In this graphical representation, the relative bias is shown alongside β-expectation tolerance limits, which are calculated from each tested concentration level using estimated bias and standard deviation of intermediate precision.[2] If these β-expectation tolerance limits remain within the predefined acceptance limits (e.g., 5% for pharmaceutical specialties), the method can be considered valid across its entire concentration range.[2] This approach is considered fully ICH compliant and provides a stronger guarantee of the quality, reliability, and accuracy of individual results for the intended use of the NIR method.[2] It has been shown that methods with seemingly low RMSEP values might not be declared valid when assessed via accuracy profiles, underscoring that a small RMSEP alone is insufficient to guarantee the validity of NIR methods.[2] This highlights a maturation in regulatory and scientific understanding of multivariate data validation. Simply fitting a model with a high R^2 or low RMSE is no longer enough; the focus has shifted to demonstrating the fitness for

METASPEQ NIR

purpose of individual results across the entire analytical range, particularly regarding accuracy and reliability. This implies that pharmaceutical companies must adopt more sophisticated statistical validation tools beyond basic chemometrics, requiring deeper statistical expertise within their analytical teams. It ensures that NIR methods, especially those used for quantitative release, provide truly reliable and accurate results, reducing the risk of out-of-specification products reaching the market.

2. Precision (Repeatability, Intermediate Precision)

Precision is assessed through repeated measurements.

- **Repeatability:** This is evaluated by performing repeated analyses, with the sample being removed and repositioned in the holder between each measurement to account for potential variations in sample presentation.[9] The standard deviation of these repeat measurements serves as a useful metric.[13]
- **Intermediate Precision:** This is determined by analyzing samples under varied conditions, such as by different analysts or on different days, to assess the method's consistency under typical operational variations.[13] For both, samples should cover the expected range of variation, with multiple measurements per sample.[13]

3. Specificity/Selectivity (Interference, Outlier Rejection)

Specificity for NIR methods is demonstrated by comparing the drug substance spectrum with the loading plots of the developed model, ensuring they correspond appropriately after identical pretreatment.[9] A key element of specificity is the method's ability to reject outliers, such as excipients or structurally similar compounds, that are not covered by the multivariate procedure.[9] For qualitative procedures, demonstrating correct pass/fail results with both positive controls (samples of known identity confirmed by independent reference testing) and negative controls (placebos or spectrally similar samples) is crucial.[13]

4. Linearity and Reportable Range (Graphical Assessment, Residual Analysis)

Linearity is assessed by comparing the NIR results for external validation samples against the results obtained from a reference analytical procedure.[9] Graphically, a correlation coefficient close to 1 and a y-intercept near 0 (if applicable) typically indicate acceptable linearity.[13] However, a high correlation coefficient alone is not sufficient to guarantee comparability and exchangeability of the analytical method.[2] ICH Q2(R2) emphasizes the importance of also assessing how the analytical procedure error (residuals) changes across the calibration range, often through graphical plots of residuals versus the actual data.[2] The reportable range, derived from product specifications, must encompass the upper and lower specification or

METASPEQ NIR

reporting limits, demonstrating acceptable accuracy, precision, and specificity within this interval.[10]

5. Robustness (Impact of Deliberate Variations and Matrix Effects)

Robustness, the capacity of an analytical procedure to remain unaffected by small, deliberate variations in method parameters, is primarily addressed during the calibration model development phase.[9] This involves deliberately incorporating anticipated sources of variability into the calibration data set. Examples of such variations include raw materials from various sources, different water content levels, variations in tablet hardness, and changes in sample orientation within the holder, as well as different operating and environmental conditions.[9] The robustness of the method is then confirmed during validation by using validation samples that include the range of variability expected in commercial production.[13] The model should consistently meet its expected performance criteria despite these variations.[9] It is recognized that NIR measurements are sensitive to changes in tablet composition and properties that fall outside the variation present in the original calibration set.[9]

Table 2: Acceptable Limits and Criteria for Key NIR Validation Parameters (ICH Q2(R2) and FDA Perspectives)

Validation Parameter	ICH Q2(R2) Criteria (Spectroscopic Methods, Multivariate Calibration)		FDA Guidance Expectations (NIR Analytical Procedures)			
Accuracy	- Typically reported as Standard Error of Prediction (SEP or RMSEP).[9]	- Comparison with orthogonal procedure across the range (e.g., 5 concentrations, 3 replicates).9	- Accuracy profile: β-expectation tolerance limits within acceptance limits (e.g., 5% for pharmaceutical specialties).2	- Compare NIR results with suitable reference analytical procedure.[13]	- SEP can measure accuracy; significant differences between SEC and SEP or biases require investigation.13	- Independent validation set should span suitable concentration range.13
Precision	- **Repeatab**	-	- **Repeatab**	- Samples	-	

PEONIR

	ility: Repeated analysis with sample removal from holder between measurements.[9]	Standard deviation of repeat measurements is useful.13	**ility:** Standard deviation of repeat measurements.[13]	cover expected variation, multiple measurements per sample, reposition sample if possible.13	Intermediate Precision: Determine with different analysts/days.13	
Specificity/Selectivity	- Absence of interference: Comparison of drug substance spectrum and loading plots.[9]	- Rejection of outliers (e.g., excipient, analogues) not covered by the multivariate procedure.9	- Verified if main features of loadings plots correspond to analyte's NIR spectrum loadings plots (pretreated identically).[13]	- Ability to reject outliers.13	- For qualitative procedures: Demonstrate correct pass/fail with positive and negative controls.13	
Linearity	- Relationship between predicted and reference values.[9]	- Information on how analytical procedure error (residuals) changes across calibration range (e.g., graphical plots).9	- Correlation coefficient near 1, y-intercept near 0 (if applicable).13	- Compare NIR results for external validation samples to reference procedure results.[13]	- Correlation coefficient near 1 and y-intercept near 0 indicate acceptable linearity.13	
Range	- Interval		-			

	between lowest and highest results with suitable precision, accuracy, and response.[9]	- Reportable range: All values from lowest to highest reportable result with suitable precision and accuracy. 9	Appropriate range depends on attribute evaluated.[13]	- Reportable range should be inclusive of upper and lower specification/reporting limits.10		
Robustness	- Capacity to meet expected performance criteria during normal use.[9]	- Deliberate variation of parameters (chemical/ physical factors impacting NIR spectrum/ model prediction) represented in data sets.9	- NIR measurements sensitive to changes outside calibration set variation.9	- Addressed during calibration model development by including anticipated variability sources (raw materials, operating/ environmental conditions).[13]	- Confirmed during validation using samples with commercial production variability. 13	

IV. Advanced Considerations in NIR Method Validation and Lifecycle Management

A. Calibration Transfer Between Instruments

1. Overview of Common Transfer Methods and Their Performance

A significant challenge in implementing NIR spectroscopy across multiple manufacturing sites or with different instruments is the variability in spectral signals, even from the same sample, due to differences in spectrometer structure, principles, and environmental factors.[15] To overcome this, effective calibration transfer is essential, as it eliminates the time-consuming and labor-intensive process of reconstructing models for each instrument.[15]

Several methods are commonly employed for calibration transfer:

- **Slope/Bias Correction:** This method involves adjusting an existing calibration model by applying a slope and bias correction.[16] For effective transfer using this technique, a larger variation in the content of the active ingredient and a greater number of samples are typically required compared to other methods.[16]
- **Local Centring:** This method adjusts the spectral data by centering it around a local mean.[16] It is often considered a preferred transfer method due to its excellent performance and simplicity, requiring no optimization and only a few transfer samples.[16] A notable advantage is that the transfer samples do not need to vary in their active ingredient content.[16]
- **Piecewise Direct Standardization (PDS):** PDS is a more complex calibration transfer method that involves standardizing the spectra piecewise.[16] Successful implementation of PDS requires optimization of the number and selection of transfer samples, along with various method-specific factors.[16]

Studies have shown that these three calibration transfer methods can perform equally well, demonstrating the feasibility of transferring calibrations between NIR instruments of different configurations or even different types (e.g., dispersive NIR and Fourier Transform (FT) instruments) without compromising the prediction ability of the original calibration.[16]

2. Strategies for Ensuring Robustness Across Different Instruments

Ensuring robustness across different instruments involves strategies that address the inherent variability in spectral signals. Calibration transfer directly tackles signal drift and changes in absorption peak shape caused by differences in spectrometer hardware and environmental conditions.[15] Beyond traditional algorithms, advanced

METASPEQ NIR

approaches like the Stability-Analysis-Based Feature Selection (SAFS) algorithm are being developed. SAFS extracts stable spectral band information between master and slave instruments, significantly improving the prediction accuracy and robustness of the slave model.[15] Modern NIR instruments also contribute to robustness by offering features such as direct method transfer capabilities, inherent long-term stability, and automated performance validation programs (e.g., OVP software) that ensure consistent high-quality results.[17]

The necessity and demonstrated feasibility of calibration transfer imply that NIR methods can be effectively deployed across a global manufacturing network, ensuring consistency and comparability of results from different sites and instruments.[15] This capability is crucial for large pharmaceutical companies with multiple manufacturing sites, enabling centralized method development and standardized quality control globally. It fosters a truly "networked" quality assurance system, reducing the burden of site-specific validation and accelerating technology adoption across the enterprise.

B. Mitigating Matrix Effects in Pharmaceutical Formulations

1. Identification of Influencing Factors (e.g., Particle Size, Compression Force)

In transmission NIR spectroscopy, the sample matrix itself can significantly influence quantitative assessment. Factors such as the particle size of the drug substance (DS), the particle size of the filler (excipient), and the compression force applied during tablet formation can all affect the NIR spectra.[18] Principal component analysis of NIR spectra has revealed that these physical factors, in addition to drug substance content, impact the spectral data.[18] For instance, the particle size of the filler has been shown to have a particularly large effect on the prediction of drug substance content.[18] These matrix effects can introduce variability and potentially compromise the accuracy of quantitative predictions if not properly addressed.

2. Approaches to Incorporate Variability into Calibration Models

The most effective approach to mitigate matrix effects and ensure robust predictions is to incorporate all anticipated matrix variations directly into the calibration set during the model development phase.[18] This means including samples with different particle sizes (of both drug substance and filler), varying compression forces, and a comprehensive range of drug substance content levels.[18] When such a comprehensive array of matrix variations is included in the multivariate calibrations, good predictions can be obtained for all types of tablets using NIR spectroscopy, effectively mitigating the influence of these effects.[18] Additionally, the application of appropriate spectral pretreatments, such as derivatives or normalization, can further minimize the influence of physical attribute differences and enhance the spectral effects related to

METASPEQ NIR

chemical composition, thereby contributing to model robustness.[13]

The fact that matrix effects significantly influence NIR spectra and quantitative predictions, and that these effects can be mitigated by including such variations in the calibration models, indicates that this is not merely a validation step but an integral part of the *design* of a robust NIR analytical procedure. It represents a shift from simply "testing for robustness" to "designing for robustness" from the outset. This highlights the importance of a thorough understanding of the product and process, as per ICH Q14 principles, during NIR method development. It implies that analytical method development for NIR is inherently intertwined with pharmaceutical development, requiring cross-functional collaboration between formulation scientists, process engineers, and analytical chemists to define the design space and ensure the calibration model is truly representative of commercial manufacturing variability.

C. Lifecycle Management and Continuous Process Verification (CPV)

1. Role of Process Analytical Technology (PAT) in CPV

Process validation in the pharmaceutical industry is increasingly viewed as an ongoing, dynamic process rather than a static, one-time event.[5] This evolving perspective, known as Continuous Process Verification (CPV), aims to ensure that the manufacturing process remains effective, efficient, and aligned with evolving regulatory standards throughout the entire product lifecycle.[5] Process Analytical Technology (PAT) tools, such as NIR spectroscopy, are crucial enablers of CPV.[5] CPV involves implementing extensive in-line, on-line, or at-line controls to monitor process performance and product quality of each batch in real-time.[5] This necessitates the continuous collection of relevant data on quality attributes of incoming materials, in-process materials, and finished products, including the assessment of Critical Quality Attribute (CQA) and Critical Process Parameter (CPP) trends.[5] The use of PAT applications like NIR spectroscopy, often integrated with feedback control loops and multivariate statistical process control (MSPC), is fundamental to achieving this continuous monitoring and control.[5]

2. Ongoing Monitoring, Model Maintenance, and Revalidation Triggers

Regulatory bodies, including the FDA, expect that NIR analytical procedures are appropriately followed, maintained, and updated throughout the drug product's lifecycle in accordance with Current Good Manufacturing Practice (CGMP) requirements.[11] This necessitates the establishment of clear procedures for hardware maintenance, continuous monitoring of calibration model predictions and diagnostics to detect changes (such as trends or shifts), and the recognition of circumstances that may warrant revision of the calibration model.[11] When revisions are deemed

METASPEQ NIR

necessary, the model must be revised and revalidated.[11] High-level summaries of these lifecycle maintenance plans for NIR models should be submitted in regulatory applications, while detailed plans and records of software version changes must be diligently maintained at the manufacturing site and made available for inspection.[13] Furthermore, changes to an analytical procedure, whether minor or significant, may necessitate partial or full revalidation, with the extent of revalidation justified by science and risk-based principles.[10]

The shift towards Continuous Process Verification (CPV) and the explicit identification of NIR as a critical PAT tool for enabling CPV signify a transition from a reactive, batch-release quality control system to a proactive, real-time quality assurance system.[5] This implies that regulatory bodies are increasingly comfortable with and encouraging continuous monitoring and adaptive control strategies. This approach can lead to real-time product release, significantly reducing inventory holding times and improving supply chain responsiveness. It also offers potential for greater regulatory flexibility in post-approval change management, as robust lifecycle data can justify changes more easily.[6] This fosters a culture of continuous improvement and process understanding within pharmaceutical manufacturing.

V. Best Practices and Implementation Challenges for NIR Validation

A. Strategic Approaches for Efficient and Compliant NIR Validation

Achieving efficient and compliant NIR validation in the pharmaceutical industry requires a strategic and integrated approach. A primary best practice involves the systematic application of **Quality Risk Management (QRM)** throughout the entire validation lifecycle.[5] This entails identifying, assessing, and mitigating potential risks, thereby focusing validation efforts on critical process parameters (CPPs) and critical quality attributes (CQAs).[5] A thorough understanding of the manufacturing process and its critical quality attributes is fundamental to this risk-based approach.[19]

Another strategic element is the careful **selection of appropriate PAT tools and techniques**, such as NIR, ensuring they are fit for purpose and meet criteria for accuracy, precision, and robustness.[19] A robust

data analysis and interpretation plan must be developed to derive meaningful insights from the real-time data generated by NIR systems.[20] Seamless

integration of PAT systems with existing manufacturing systems and processes

METASPEQ NIR

is also crucial for operational efficiency and data flow.[19]

The **digitalization of process validation** is increasingly encouraged by regulatory authorities as a best practice.[5] This involves leveraging digital technologies for data registry, collection, and storage, enabling real-time monitoring through dashboards, and automating report generation to minimize human input and error.[3] Finally, ensuring that all manufacturing processes are managed by

trained personnel in strict accordance with GMP guidelines is paramount for maintaining the validated state.[5]

B. Addressing Common Challenges (Regulatory Hurdles, Technical Complexities, Resource Constraints)

Despite the clear benefits of NIR spectroscopy in pharmaceutical manufacturing, its implementation and validation are not without challenges.

Regulatory Hurdles: While regulatory guidelines are evolving to embrace PAT, navigating the complex and often nuanced requirements remains a significant challenge for pharmaceutical companies.[19] This includes the need to develop comprehensive PAT implementation plans that meet specific regulatory expectations, meticulously validate the PAT system, ensure robust data integrity, and provide adequate training to personnel on PAT principles and practices.[20]

Technical Challenges:

- **Sensor Selection:** The criticality of selecting appropriate NIR sensors that are accurate, precise, and robust for specific applications within the manufacturing environment is a key technical consideration.[19]
- **Data Management:** PAT tools generate large volumes of real-time data, and effectively managing, analyzing, and interpreting this data presents a substantial technical challenge.[19]
- **System Integration:** Integrating new NIR PAT systems with existing manufacturing equipment and IT infrastructure can be complex and requires significant investment in IT resources.[19]
- **Calibration Transfer:** Ensuring the robustness and transferability of calibration models across different instruments and manufacturing environments remains a technical hurdle that requires specialized methods and expertise.[15]
- **Matrix Effects:** Accounting for and mitigating the influence of physical and chemical variations in the sample matrix on NIR spectral signals requires sophisticated model development and validation strategies.[18]

METASPEQ NIR

Cultural and Organizational Barriers: The successful adoption of PAT, including NIR, necessitates a fundamental shift towards a culture of quality and innovation within an organization.[20] This cultural transformation can be a significant internal hurdle, requiring strong leadership and commitment.

Cost and Resource Constraints: Implementing and maintaining advanced PAT systems like NIR involves substantial investment in technology, specialized infrastructure, and the recruitment and training of skilled personnel.[19] These financial and human resource constraints can be a barrier for some organizations.

Despite the clear benefits of improved product quality, reduced costs, and increased efficiency, PAT/NIR implementation faces significant challenges across regulatory, technical, cultural, and cost domains.[19] However, regulatory agencies are increasingly emphasizing PAT and continuous process verification, and the growing demand for personalized medicine, which often involves smaller batches and requires real-time control, is further driving PAT adoption.[19] Overcoming these challenges is not merely about achieving compliance but represents a strategic investment in future-proofing pharmaceutical manufacturing. The initial hurdles, while substantial, lead to long-term gains in quality, efficiency, and adaptability. This suggests that companies that proactively invest in and successfully implement NIR PAT are positioning themselves for a competitive advantage in a rapidly evolving regulatory and market landscape. The challenges, therefore, represent barriers to entry for less adaptable organizations, while simultaneously creating opportunities for leaders in pharmaceutical manufacturing.

VI. Conclusion

Near-Infrared (NIR) spectroscopy has solidified its position as a powerful and indispensable Process Analytical Technology (PAT) tool in modern pharmaceutical manufacturing. Its non-destructive, real-time, and multiparametric capabilities enable continuous monitoring of critical quality attributes and process parameters, fundamentally shifting quality control from a reactive, end-product testing paradigm to a proactive, quality-by-design approach. This transition facilitates enhanced operational efficiency, reduced waste, and accelerated product release, ultimately contributing to improved patient safety through consistent product quality.

The regulatory landscape for NIR method validation is comprehensively defined by the International Council for Harmonisation (ICH) Q2(R2) and the U.S. Food and Drug Administration (FDA) guidance on Near Infrared Analytical Procedures. These guidelines, developed in parallel with ICH Q14, emphasize a science- and risk-based

METASPEQ NIR

lifecycle approach to analytical procedure validation. They explicitly include spectroscopic techniques like NIR, acknowledging the multivariate nature of their data and requiring rigorous external validation beyond internal model optimization. This regulatory harmonization and modernization streamline global drug development and foster innovation.

Meticulous method development, robust validation, and ongoing lifecycle management are paramount for ensuring the fitness-for-purpose of NIR methods. This includes comprehensive calibration set construction accounting for process and material variability, rigorous external validation with independent samples, and continuous monitoring of model performance. The evolution towards sophisticated statistical tools like accuracy profiles underscores the increasing statistical rigor required to demonstrate the reliability of individual results. Furthermore, the ability to perform calibration transfer between instruments and effectively mitigate matrix effects are critical for widespread, consistent deployment of NIR technology across manufacturing networks.

While the implementation of NIR PAT systems presents challenges related to regulatory navigation, technical complexities, cultural adoption, and resource investment, overcoming these hurdles is a strategic imperative. Companies that proactively invest in and successfully integrate NIR into their quality systems are not only ensuring compliance but also gaining a competitive advantage in a dynamic market demanding greater efficiency, agility, and product quality. The sustained commitment to these guidelines and best practices will continue to drive advancements in pharmaceutical manufacturing, leading to safer, more effective, and more accessible medicines.

References

1. Primer on NIR Spectroscopy as a PAT tool in the Tablet Manufacture ..., accessed on June 25, 2025, https://www.americanpharmaceuticalreview.com/Featured-Articles/116128-Primer-on-NIR-Spectroscopy-as-a-PAT-tool-in-the-Tablet-Manufacture-Process/
2. Validation methodologies of near infrared spectroscopy ... - ORBi, accessed on June 25, 2025, https://orbi.uliege.be/bitstream/2268/143602/1/PFCHAVEZ_EurPharmReview_2013.pdf
3. Quantitative analysis of pharmaceutical forms, accessed on June 25, 2025, https://www.iris-eng.com/quantitative-analysis-of-pharmaceutical-forms/
4. NIR SPECTROSCOPY PAT SENSORS - InnoPharma Technology, accessed on June 25, 2025, https://www.innopharmatechnology.com/nir-spectroscopy-pat-sensors/

METASPEQ NIR

5. Best Practices for Process Validation in the Pharmaceutical Industry, accessed on June 25, 2025, https://www.valgenesis.com/blog/best-practices-for-process-validation-in-the-pharmaceutical-industry
6. ICH Q2(R2) Validation of Analytical Procedures: An Overview of the Revised Guideline, accessed on June 25, 2025, https://www.qbdgroup.com/en/blog/ich-q2r2-validation-of-analytical-procedures-an-overview-of-the-revised-guideline/
7. Streamlining Analytical Procedure Development, Validation, and ..., accessed on June 25, 2025, https://ispe.org/pharmaceutical-engineering/ispeak/streamlining-analytical-procedure-development-validation-and
8. Q2(R2) Validation of Analytical Procedures and Q14 Analytical Procedure Development; International Council for Harmonisation; Guidances for Industry; Availability - Federal Register, accessed on June 25, 2025, https://www.federalregister.gov/documents/2024/03/07/2024-04834/q2r2-validation-of-analytical-procedures-and-q14-analytical-procedure-development-international
9. Validation of Analytical Procedures Q2(R2) - ICH, accessed on June 25, 2025, https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf
10. Validation of Analytical Procedure Q2(R2) - ICH, accessed on June 25, 2025, https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf
11. FDA Publishes New Near Infrared (NIR) Guidance - ECA Academy, accessed on June 25, 2025, https://www.gmp-compliance.org/gmp-news/fda-publishes-new-near-infrared-nir-guidance
12. Development and Submission of Near Infrared Analytical Procedures; Guidance for Industry; Availability - Federal Register, accessed on June 25, 2025, https://www.federalregister.gov/documents/2021/08/09/2021-16930/development-and-submission-of-near-infrared-analytical-procedures-guidance-for-industry-availability
13. Development and Submission of Near Infrared Analytical ... - FDA, accessed on June 25, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-submission-near-infrared-analytical-procedures
14. Development and Submission of Near Infrared Analytical Procedures; Draft Guidance for Industry; Availability - Federal Register, accessed on June 25, 2025, https://www.federalregister.gov/documents/2015/03/31/2015-07266/development-and-submission-of-near-infrared-analytical-procedures-draft-guidance-for-industry
15. Algorithm of Stability-Analysis-Based Feature Selection for NIR ..., accessed on June 25, 2025, https://www.mdpi.com/1424-8220/22/4/1659
16. Transfer of NIR calibrations for pharmaceutical formulations ..., accessed on June 25, 2025, https://pubmed.ncbi.nlm.nih.gov/16406454/

METASPEQ NIR

17. MATRIX-F II FT-NIR Spectrometer - Bruker, accessed on June 25, 2025, https://www.bruker.com/en/products-and-solutions/infrared-and-raman/ft-nir-spectrometers/matrix-f-ft-nir-spectrometer.html
18. Matrix Effects in Quantitative Assessment of Pharmaceutical Tablets ..., accessed on June 25, 2025, https://www.researchgate.net/publication/274008453_Matrix_Effects_in_Quantitative_Assessment_of_Pharmaceutical_Tablets_Using_Transmission_Raman_and_NIR_Spectroscopy
19. Revolutionizing Pharma with PAT - Number Analytics, accessed on June 25, 2025, https://www.numberanalytics.com/blog/revolutionizing-pharma-with-process-analytical-technology
20. PAT in Pharma: A Comprehensive Guide - Number Analytics, accessed on June 25, 2025, https://www.numberanalytics.com/blog/ultimate-guide-to-process-analytical-technology-in-pharmaceutical-sciences

METASPEQ NIR